Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161232 | 0.94 | MET (0.61) | METDYRK3CCNA2CDK2CDK5 | |
| SCHEMBL4514006 | 0.88 | MET (0.44) | METDYRK3CCNA2CDK2CDK5 | |
| SCHEMBL3416455 | 0.84 | MET (0.49) | METDYRK3CCNA2CDK2CDK5 | |
| SCHEMBL3409421 | 0.82 | MET (0.61) | MET | |
| SCHEMBL1161016 | 0.82 | MET (0.61) | MET | |
| SCHEMBL3411715 | 0.82 | MET (0.48) | METDYRK3CCNA2CDK2CDK5 | |
| SCHEMBL1163159 | 0.79 | MET (0.75) | MET | |
| SCHEMBL1660351 | 0.78 | MET (0.55) | MET | |
| SCHEMBL3415985 | 0.77 | MET (0.59) | METDYRK3CCNA2CDK2CDK5 | |
| SCHEMBL1161103 | 0.75 | MET (0.67) | METDYRK3CCNA2CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |